Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Policy / Regulatory

NHSA Unveils 2023 Flying Inspection Plan for Medical Insurance Fund Oversigh

Fineline Cube Jul 17, 2023

The National Healthcare Security Administration (NHSA) has released its 2023 Basic Medical Insurance (BMI) Fund...

Company Drug

Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval

Fineline Cube Jul 17, 2023

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial...

Company Drug

Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina

Fineline Cube Jul 17, 2023

Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III...

Company Drug

Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment

Fineline Cube Jul 17, 2023

China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient...

Company Drug Policy / Regulatory

Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis

Fineline Cube Jul 17, 2023

Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...

Company Deals

Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical

Fineline Cube Jul 14, 2023

UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...

Company

Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results

Fineline Cube Jul 14, 2023

Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...

Company Deals

InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination

Fineline Cube Jul 14, 2023

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based...

Company Drug

GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China

Fineline Cube Jul 14, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...

Company Medical Device

Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA

Fineline Cube Jul 14, 2023

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National...

Company Deals

GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs

Fineline Cube Jul 14, 2023

China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...

Company Drug

BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA

Fineline Cube Jul 13, 2023

China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer

Fineline Cube Jul 13, 2023

Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...

Company Policy / Regulatory

US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage

Fineline Cube Jul 13, 2023

The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...

Company Drug

Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA

Fineline Cube Jul 13, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Deals

DNE Group Launches $485 Million Fund for Life Sciences Park in Shanghai Pudong

Fineline Cube Jul 13, 2023

China-based infrastructure investor DNE Group has revealed that it has raised a new fund worth...

Company Deals

LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial

Fineline Cube Jul 13, 2023

Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...

Company Deals

Medidata Partners with ECCO and GoBroad to Transform Cancer Trials with Digital Tech

Fineline Cube Jul 13, 2023

Medidata, a wholly owned subsidiary of France firm Dassault Systèmes (EPA: DSY), has announced a...

Company Deals

Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential

Fineline Cube Jul 13, 2023

Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...

Company Drug

Kedrion Biopharma Achieves First Product Approval in China for Human Albumin

Fineline Cube Jul 13, 2023

Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL),...

Posts pagination

1 … 542 543 544 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.